Search Results - "García Estévez, Laura"

Enhancing global access to cancer medicines by Cortes, Javier, Perez‐García, Jose Manuel, Llombart‐Cussac, Antonio, Curigliano, Giuseppe, El Saghir, Nagi S., Cardoso, Fatima, Barrios, Carlos H., Wagle, Shama, Roman, Javier, Harbeck, Nadia, Eniu, Alexandru, Kaufman, Peter A., Tabernero, Josep, García‐Estévez, Laura, Schmid, Peter, Arribas, Joaquín

“…Globally, cancer is the second leading cause of death, with numbers greatly exceeding those for human immunodeficiency virus/acquired immunodeficiency…”
Get full text

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer by Franco-Mateos, Emma, Souza-Egipsy, Virginia, García-Estévez, Laura, Pérez-García, José, Gion, María, Garrigós, Laia, Cortez, Patricia, Saavedra, Cristina, Gómez, Patricia, Ortiz, Carolina, Cruz, Víctor L, Ramos, Javier, Cortés, Javier, Vega, Juan F

“…The binding activity of various trastuzumab biosimilars versus the branded trastuzumab towards the glycosylated extracellular domain of the human epidermal…”
Get full text

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer by Jhaveri, Komal L, Bellet, Meritxell, Turner, Nicholas C, Loi, Sherene, Bardia, Aditya, Boni, Valentina, Sohn, Joohyuk, Neilan, Tomas G, Villanueva-Vázquez, Rafael, Kabos, Peter, García-Estévez, Laura, López-Miranda, Elena, Pérez-Fidalgo, J Alejandro, Pérez-García, Jose M, Yu, Jiajie, Fredrickson, Jill, Moore, Heather M, Chang, Ching-Wei, Bond, John W, Eng-Wong, Jennifer, Gates, Mary R, Lim, Elgene

“…Giredestrant is an investigational next-generation, oral, selective estrogen receptor antagonist and degrader for the treatment of estrogen receptor-positive…”
Get full text

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) by Mayer, Ingrid A, Prat, Aleix, Egle, Daniel, Blau, Sibel, Fidalgo, J Alejandro Pérez, Gnant, Michael, Fasching, Peter A, Colleoni, Marco, Wolff, Antonio C, Winer, Eric P, Singer, Christian F, Hurvitz, Sara, Estévez, Laura García, van Dam, Peter A, Kümmel, Sherko, Mundhenke, Christoph, Holmes, Frankie, Babbar, Naveen, Charbonnier, Laure, Diaz-Padilla, Ivan, Vogl, Florian D, Sellami, Dalila, Arteaga, Carlos L

“…Addition of alpelisib to fulvestrant significantly extended progression-free survival in -mutant, hormone receptor-positive (HR ) advanced/metastatic breast…”
Get full text

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status by García-Estévez, Laura, Cortés, Javier, Pérez, Silvia, Calvo, Isabel, Gallegos, Isabel, Moreno-Bueno, Gema

“…Breast cancer is the most common tumor in women worldwide, and an increasing public health concern. Knowledge of both protective and negative risk factors is…”
Get full text

The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer by García-Estevez, Laura, González-Martínez, Silvia, Moreno-Bueno, Gema

“…Adipose tissue secretes various peptides, including leptin. This hormone acts through the leptin receptor (Ob-R), which is expressed ubiquitously on the…”
Get full text

SEOM clinical guidelines for the treatment of metastatic breast cancer by Álvarez López, Isabel, de la Haba Rodríguez, Juan, Ruiz Simón, Amparo, Bellet Ezquerra, Meritxell, Calvo Martínez, Lourdes, García Estévez, Laura, Rodríguez Lescure, Álvaro, Isla Casado, Dolores

“…Patients with metastatic breast cancer have a wide number of treatment options, including medical, surgical, and supportive care measures. Treatment decisions…”
Get full text

Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy by Apellániz-Ruiz, María, Lee, Mi-Young, Sánchez-Barroso, Lara, Gutiérrez-Gutiérrez, Gerardo, Calvo, Isabel, García-Estévez, Laura, Sereno, María, García-Donás, Jesús, Castelo, Beatriz, Guerra, Eva, Leandro-García, Luis J, Cascón, Alberto, Johansson, Inger, Robledo, Mercedes, Ingelman-Sundberg, Magnus, Rodríguez-Antona, Cristina

“…Paclitaxel, a widely used chemotherapeutic drug, can cause peripheral neuropathies leading to dose reductions and treatment suspensions and decreasing the…”
Get full text

Current controversies in the management of breast cancer by Tusquets, Ignasi, García-Estévez, Laura, Adrover, Encarna, Calvo, Lourdes, Álvarez, Isabel, García Mata, Jesús, Fernández, Yolanda, Margueli, Mireia, Seguí, Miquel Ángel, Rodríguez, César, Rodríguez Lescure, Álvaro, Colomer, Ramon, Gascón, Pere, Martín, Miguel, Alba, Emilio, Barnadas, Agusti, Llombart, Antonio, Albanell, Joan, Lluch, Ana

“…The following manuscript summarises the content of the Breast Symposium that was held in May 2008 in Barcelona in which four controversies regarding the…”
Get full text

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays by Hyams, David M., Schuur, Eric, Angel Aristizabal, Javier, Bargallo Rocha, Juan Enrique, Cabello, Cesar, Elizalde, Roberto, García‐Estévez, Laura, Gomez, Henry L., Katz, Artur, Nuñez De Pierro, Aníbal

“…Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision‐making. This review details the development and…”
Get full text

Updating the role of obesity and cholesterol in breast cancer by Garcia-Estevez, Laura, Moreno-Bueno, Gema

“…Breast cancer is the second most common cause of cancer-related death among women. Advances in our understanding of the disease have translated into better…”
Get full text

Abstract P5-18-07: Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545) ± palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer by Neilan, Tomas G, Villanueva-Vázquez, Rafael, Bellet, Meritxell, López-Miranda, Elena, García-Estévez, Laura, Kabos, Peter, Bond, John, Gates, Mary R, Chang, Ching-Wei, Boni, Valentina

“…Background Targeting the activity of the estrogen receptor and/or estrogen synthesis is a standard primary treatment for eligible patients with estrogen…”
Get full text

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis by Juric, Dejan, Munster, Pamela N., Campone, Mario, Ismail-Khan, Roohi, García-Estevez, Laura, Hamilton, Erika Paige, Becerra, Carlos, De Boer, Richard H., Hui, Rina, Goncalves, Anthony, Wang, Yingbo, Dhuria, Shyeilla V., Kalimi, Ghulam H., Rodriguez Lorenc, Karen Cristina, Mayer, Ingrid A.

“…Abstract only…”
Get full text

Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors by Lluch, Ana, Álvarez, Isabel, Muñoz, Montserrat, Seguí, Miguel Ángel, Tusquets, Ignasi, García-Estévez, Laura

“…Abstract In spite of recent advances in the treatment of metastatic breast cancer, this disease remains essentially incurable. Anthracyclines and taxanes have…”
Get full text

Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC) by Jhaveri, Komal L., Boni, Valentina, Sohn, Joohyuk, Villanueva-Vásquez, Rafael, Bardia, Aditya, Schmid, Peter, Lim, Elgene, Patel, Jaymin M., Perez-Fidalgo, Jose Alejandro, Loi, Sherene, Im, Seock-Ah, Kshirsagar, Smita, Gates, Mary R., Bond, John, Eng-Wong, Jennifer, Chang, Ching-Wei, Turner, Nicholas C., Lopez Miranda, Elena, García-Estévez, Laura, Bellet, Meritxell

“…Abstract only 1017 Background: Targeting ER activity and/or E synthesis is a mainstay of ER+ BC treatment, but many pts relapse during/after adjuvant endocrine…”
Get full text

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer by Traina, Tiffany A, Miller, Kathy, Yardley, Denise A, Eakle, Janice, Schwartzberg, Lee S, O'Shaughnessy, Joyce, Gradishar, William, Schmid, Peter, Winer, Eric, Kelly, Catherine, Nanda, Rita, Gucalp, Ayca, Awada, Ahmad, Garcia-Estevez, Laura, Trudeau, Maureen E, Steinberg, Joyce, Uppal, Hirdesh, Tudor, Iulia Cristina, Peterson, Amy, Cortes, Javier

“…Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit…”
Get full text

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial by Kim, Sung-Bae, Dent, Rebecca, Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R, Isakoff, Steven J, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew J, Kapp, Amy V, Chan, Wai Y, Singel, Stina M, Maslyar, Daniel J, Baselga, José, Kim, Sung-Bae, Lee, Keun Seok, Im, Seock-Ah, Espié, Marc, Wang, Hwei-Chung, Blau, Sibel, Dent, Rebecca, Tan, Antoinette, Sohn, Joo Hyuk, De Laurentiis, Michelino, Estevez, Laura Garcia, Huang, Chiun-Sheng, Romieu, Gilles, Velez, Michel, Villanueva, Rafael, Conte, Pier Franco, Dakhil, Shaker, Debled, Marc, Martin, Antonio Gonzalez, Hurvitz, Sara, Kim, Jee Hyun, Levy, Christelle, Oliveira, Mafalda, Rovira, Pedro Sanchez, Seo, Jae Hong, Valero, Vicente, Vidal, Gregory, Wong, Andrea, Allison, Mary Ann K, Figlin, Robert, Chan, David, Chen, Shin-Cheh, Chen, Yen-Hsun, Cobleigh, Melody, De Braud, Filippo, Dirix, Luc, Hansen, Vincent, Bessard, Anne Hardy, Iannotti, Nicholas, Isakoff, Steven, Lawler, William, Montaño, Alvaro, Salkini, Mohamad, Seigel, Leonard

“…The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast…”
Get full text

Abstract P5-02-38: Leptin receptor (Ob-R)/leptin axis significantly modulates tumour-infiltrating lymphocytes (TILs) and PD-1 expression in early HER2+ breast cancer (BC) emerging as a new surrogate marker for immunotherapy by García-Estévez, Laura, Fernández, Adela, Palacios, José, Sampayo, Miguel, Calvo, Isabel, Díaz, Eva, González, Marta, Pérez-Míes, Belén, González, Silvia, Pérez-García, José Manuel, Cortés, Javier, Moreno-Bueno, Gema

“…Leptin receptor (Ob-R)/leptin axis significantly modulates tumour-infiltrating lymphocytes (TILs) and PD-1 expression in early HER2+ breast cancer (BC)…”
Get full text

Predictive Role of Leptin Receptor (Ob-R) Overexpression in Patients with Early Breast Cancer Receiving Neoadjuvant Systemic Treatment by García-Estévez, Laura, Calvo, Isabel, Pérez, Silvia, Gallegos, Isabel, Díaz, Eva, Sampayo-Cordero, Miguel, Oltra, Sara S, Moreno-Bueno, Gema

“…The primary aim of this retrospective study was to investigate the correlation between the immunohistochemical expression of Ob-R (leptin receptor) with pCR…”
Get full text

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer by Ross, L., Eisen, A., Elsafy, F., Fielding, A., Friedman, S., Gianni, L., Phillips, K.-A., Singer, C.F., Toi, M., Park, Y.H., Yang, H., Mailliez, A., Nagy, T., Sonke, G.S., Sun, Q., Colleoni, M.A., Kaufman, B., Cameron, D., Campbell, C., Sevelda, Paul, Öhler, Leopold, Rumpold, Holger, Rautenberg, Beate, Boadle, David, Mackey, John, Niraula, Saroj, Randal d’Hondt, Papadimitriou, Konstantinos, Lazzaro, Mauricio Fernández, Pilnik, Norma, Varela, Mirta, Darsow, Maren, Park-Simon, Tjoung-Won, Terhaag, Jürgen, Salat, Christoph, Dieterich, Max, García Sáenz, José Ángel, Lanza, Angels Arcusa, Quiroga, Vanesa, Jañez, Noelia Martínez, Crusades, Gema Llort, Rodríguez, César, Cretella, Elisabetta, Jegannathen, Apurna, Ishida, Kazushige, Watanabe, Junichiro, Takada, Masahiro, Nakamura, Seigo, Aogi, Kenjiro, Tsugawa, Koichiro, Seaward, Samantha A., Carney, Jennifer Fu, Bobolis, Kristie A., Eisenberg, Peter D., Hofstatter, Erin W., McCarron, Edward C., Herbolsheimer, Pia, Meisel, Jane L., Jones, Cheryl F., Spector, David M., Lo, Shelly S., Cristofanilli, Massimo, Hahn, Olwen M., Oliff, Ira A., Ansari, Bilal, Sharma, Priyanka, Armstrong, Deborah K., VanderWoude, Amy, Friday, Bret E.B., T, Benjamin, Kuzma, Charles S., Radford, James E., Soori, Gamini S., Vogel, Victor G., Wilkinson, Mary, Qamar, Rubina, Loman, Niklas, Silander, Gustav, Abreu, Miguel, Ciruelos Gil, Eva María, Bermejo de las Heras, Begoña, Busch, Steffi, Thomalla, Jörg, Altena, Renske, Chen, Shou-Tung, Huang, Chiun-Sheng, Yeh, Dah-Cherng, Pottier, Virginie, Yang, Hongjian, Fu, Peifen, Wang, Yongsheng, Fan, Zhimin, Landherr, László, Yerushalmi, Rinat, Conte, Pierfranco, Ciccarese, Mariangela, Mackiewicz, Jacek, Kalinka, Ewa, Im, Seock-Ah, Lee, Kyoung Eun

“…The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo…”
Get full text